AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL
Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.
You may also be interested in...
Phase II data for antibody-drug conjugate polatuzumab vedotin in diffuse large B cell lymphoma suggest potential for a cure if the drug were given up front, Roche says on investor call after American Society of Hematology meeting.
AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.
A run of bad luck for developers of potential treatments for diffuse large B-cell lymphoma – Roche, Celgene and Novartis – has withered the late-stage pipeline for an indication that has long been in need of new therapies. Scrip and Datamonitor Healthcare take a look at what's next for the disease.